Dosing & Uses
Dosage Forms & Strengths
injection solution
- 25mcg/mL
RDA
Males or females: 45 mcg/day
Pregnancy: 50 mcg/day
Lactating: 50 mcg/day
Supplementation in Patients Receiving TPN
20-120 mcg/day administered in TPN
Molybdenum Deficiency from Prolonged TPN Support
163 mcg/day added to TPN for 21 days shown to be effective
Dosage Forms & Strengths
injection solution
- 25mcg/mL
RDA
<6 months: 2 mcg/day
6-12 months: 3 mcg/day
1-3 years: 17 mcg/day
3-8 years: 22 mcg/day
8-13 years: 34 mcg/day
>13 years: 43 mcg/day
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (1)
- baloxavir marboxil
molybdenum will decrease the level or effect of baloxavir marboxil by cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted.
Monitor Closely (2)
- omadacycline
molybdenum will decrease the level or effect of omadacycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.
- sarecycline
molybdenum will decrease the level or effect of sarecycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.
Minor (1)
- fluoride
fluoride, molybdenum. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Enhanced dental caries protection.
Adverse Effects
Frequency Not Defined
Gout-like symptoms (high dose)
Warnings
Contraindications
Copper deficient patients
Undiluted injection into peripheral vein (risk of infusion phlebitis)
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Detected in milk; use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Cofactor in xanthine oxidase (uric acid formation), aldehyde oxidase (EtOH detoxification), sulfite oxidase (sulfite detoxification)
Tetrathiomolybdate complexes with copper in GI tract & blood to decrease toxicity
Pharmacokinetics
Excretion: Urine (primarily); bile (minimal)
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
